Strait of Hormuz Oil Shipments Hit Six-Month High as U.S. Clears Mines 
U.S. Stock Futures Rise Ahead of Trump-Xi Summit, Middle East Risks Weigh 
Telix to Acquire Germany’s ITM in $1.65 Billion Radiopharma Deal 
FAA Allows Boeing to Sell 35 More 777F Freighters Beyond 2028 
Canada Eyes India Trade Deal by Year-End 
Nike Earnings at Risk as UBS Cuts Price Target to $42 
Oil Prices Rise as Houthi Strikes on Riyadh Fuel Middle East Tensions 
Bolivia Approves $1.9 Billion IMF Financing Deal 
LVMH-Hermès Dispute Deepens Over Secret 2002 Share Deal 
Westinghouse Targets $50 Billion Valuation in U.S. IPO 
FCC Approves Foreign Investment in $110B Paramount-Warner Bros. Deal 
Petrobras Joins Brazil Diesel Subsidy Program 
Canada Unveils Bill to Fast-Track Major Resource Projects 
NASA, Boeing Discuss Expanding Starliner Missions 
Oil Prices Rise as U.S.-Iran Talks Fuel Diplomacy Hopes 
Fed Rate Hike Threatens Housing as U.S. Growth Leans on AI, Citi Says 
SpaceX Nasdaq 100 Weight to More Than Double in Rebalance 
Add as a preferred source on Google
Celltrion, the South Korean pharmaceutical company, revealed that it had sealed its first deal for shipments of its Rekirona COVID-19 antibody treatment. The firm made the announcement on the supply transaction to Pakistan on Monday, May 10.
Celltrion’s Healthcare division will be managing its overseas business, so it was the company affiliate that signed the deal with Pakistan’s state-run company. The first order is for the shipment of 100,000 vials of Rekirona, which is enough for 30,000 people.
Rekirona receives approval from S. Korea’s drug safety board
As per The Korea Herald, once the vials of the COVID-19 antibody treatment have been delivered, Celltrion will also send its experts to Pakistan so they can train the local medical healthcare providers who have been assigned to administer the treatment.
In February, Celltrion’s Rekirona already received conditional approval from the drug safety board in S. Korea. With that, the medication effectively became the first locally-made treatment for coronavirus.
The treatment has been given to around 2,700 high-risk patients, which include individuals who are over 60 years of age. People with chronic diseases that affect the respiratory system were also administered with Rekirona earlier this year, and the results seem promising, or it will not be approved.
Celltrion already completed the third phase of clinical trials that was conducted in 13 countries with 1,300 volunteers. Aside from S. Korea, some of these nations are the U.S. and Spain. Now, the pharma company is hoping that its Rekirona will be able to help stop the growing number of patients in Pakistan.
Celltrion starts global rollout of its COVID-19 treatment
Yonhap News Agency reported that it is not just Pakistan that will have Celltrion’s Rekirona as there are also ongoing negotiations for supply to Europe, U.S., and more. The exports will start in Pakistan, and the distribution will eventually spread to other nations.
"Talks are also currently underway to export Rekirona to other countries in Europe and South America, as well as India," an official from Celltrion said. Meanwhile, two other pharmaceutical companies are developing similar monoclonal antibody treatment, and these are the US-based Regeneron and Eli Lilly. These are still under clinical tests, so it makes Celltrion the first to make a COVID-19 treatment available globally.
